449 people

Page 14

Miss Erin Snook

CRUK ECRIN-M3 Research Assistant
Connect with Erin

Professor Eugene Healy BA MB PhD FRCP FRSB FAoP

Professor of Dermatology

Research interests

  • Effects of sunshine (ultraviolet radiation) on skin.
  • Skin tone / skin pigmentation.
  • Skin cancer (keratinocyte cancer, melanoma).
Connect with Eugene

Dr Evangelos Bellos

Senior Lecturer in Genomic Informatics

Accepting applications from PhD students

Connect with Evangelos

Ms Faidra Laskou

NIHR Clinical Lecturer in Rheumatology
Connect with Faidra

Dr Fay Chinnery

Research Fellow (Health Tech Assmt&Mod)
Connect with Fay

Dr Felino Cagampang PhD

Associate Professor
Connect with Felino

Professor Francesco Forconi

Professor of Haematology

Accepting applications from PhD students

Connect with Francesco

Dr Franchesca Houghton

Associate Professor

Research interests

  • Pluripotent stem cells
  • Regenerative medicine
  • Preimplantation embryo development

Accepting applications from PhD students

Connect with Franchesca

Dr Gaby Vojt BSc, MSc, PhD

Research Fellow
Connect with Gaby

Professor Gareth Griffiths

Director SCTU & Prof of Clinical Trials

Research interests

  • Gareth Griffiths is Professor of Clinical Trials and directs our Southampton Clinical Trials Unit.  He works with clinicians, research groups and other scientists in the development of important clinical trials and other well-designed studies that aim to improve the treatment of a range of cancers and other diseases, and early diagnosis of cancer.
  • His works spans the different phases of clinical trials, from small dose finding and safety studies involving a handful of patients to larger trials of hundreds of patients looking at whether the treatments are better than the current standard treatments.  His early diagnosis studies include thousands of patients looking at new ways to detect cancer early.  Ultimately, these studies could help change the way that patients are treated for the better, by creating the evidence so as the new treatments becomes the standard of care for future patients treated in the NHS.
  • Phase I-III clinical trials
Connect with Gareth